GlassScriptPhysician profile
Solomon Seifu
NPI 1710397393
$37,122.71
in general payments reported to CMS, 2019-2025
25 companies · $184 in 2025
The $184 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $434 · 2020: $302 · 2021: $29K · 2022: $4,509 · 2023: $2,233 · 2024: $623 · 2025: $184.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,362 · Travel and Lodging: $678.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,361.83 |
| Travel and Lodging | $678.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $19,029.68 | 2021-2022 | |
| Abbott Laboratories | $11,380.53 | 2019-2023 | Diamondback Coronary, Aveir, Diamondback Peripheral |
| Edwards Lifesciences Corporation | $4,300.67 | 2021-2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Boston Scientific Corporation | $593.78 | 2021-2025 | Sentinel, Avvigo Guidance System, Watchman Flx |
| Abiomed | $453.41 | 2022-2024 | Impella |
| Shockwave Medical, INC | $261.88 | 2022-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Intravascular Lithotripsy (Ivl) System With The Shockwave C2+ Coronary, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Inari Medical, INC. | $252.73 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Amgen INC. | $219.24 | 2019-2023 | Repatha |
| Kestra Medical Technology Services, INC. | $149.65 | 2023-2025 | Assure Wcd |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $91.19 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $62.57 | 2019-2023 | Farxiga |
| Cardiovascular Systems INC. | $44.76 | 2022-2023 | Diamondback Coronary |
| United Therapeutics Corporation | $42.63 | 2019 | |
| Vital Connect, INC | $40.91 | 2022 | |
| Pfizer INC. | $31.58 | 2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $21.82 | 2024 | Verquvo |
| Regeneron Healthcare Solutions, INC. | $20.68 | 2024 | Evkeeza |
| Genzyme Corporation | $18.88 | 2023 | |
| Ge Healthcare | $17.76 | 2024 | |
| Chiesi USA, INC. | $16.72 | 2023 | Kengreal |
| Reflow Medical INC | $16.66 | 2023 | |
| Lexicon Pharmaceuticals, INC. | $15.05 | 2023 | Inpefa |
| Sanofi-Aventis U.S. LLC | $14.19 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $12.88 | 2019 | |
| Gilead Sciences, INC. | $12.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Solomon Seifu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.